Literature DB >> 16376647

Keratoprosthesis: the Dohlman-Doane device.

James V Aquavella1, Ying Qian, Gregory J McCormick, Jayachandra Reddy Palakuru.   

Abstract

PURPOSE: To determine the usefulness of the Dohlman-Doane type I keratoprosthesis for visual rehabilitation in cases of poor prognosis for traditional penetrating keratoplasty.
DESIGN: A retrospective, noncomparative interventional series of 25 patients who had sustained multiple graft failure or who were otherwise deemed poor candidates for conventional keratoplasty.
METHODS: Candidates were evaluated for potential acuity, intraocular pressure, inflammation, the quality of the ocular surface, and overall prognosis for penetrating keratoplasty. The keratoprosthesis was assembled and mounted on an 8.5- or 9.0-mm diameter donor corneal button and sutured into an 8.0- or 8.5-mm diameter recipient bed with 12 to 16 9-0 nylon sutures. Patients were examined on the first day and subsequently in 1 week and 1 month and then at 3-month intervals.
RESULTS: All devices were retained without dislocation or extrusion. There were no instances of endophthalmitis or surface infection. Fundus details were visible on the first postoperative day. Patients achieved their best acuity in an average of 2 months (range, 1 to 180 days). Improvement in acuity was observed in an average of 13 days (range, 1 to 60 days). Retroprosthetic membranes occurred in three cases, with multiple recurrences in one instance. Visual acuity ranged from no light perception to 20/25.
CONCLUSION: We conclude that this prosthesis can be implanted routinely and maintained with minimal complications in poor prognosis keratoplasty, which presents the potential for visual rehabilitation.

Entities:  

Mesh:

Year:  2005        PMID: 16376647     DOI: 10.1016/j.ajo.2005.06.041

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  17 in total

1.  Boston type 1 keratoprosthesis: the New York Eye and Ear experience.

Authors:  A P Patel; E I Wu; D C Ritterband; J A Seedor
Journal:  Eye (Lond)       Date:  2011-12-16       Impact factor: 3.775

2.  An eye opening technique.

Authors:  Janice Hopkins Tanne
Journal:  BMJ       Date:  2006-06-24

3.  Boston type 1 keratoprosthesis for severe blinding vernal keratoconjunctivitis and Mooren's ulcer.

Authors:  Sayan Basu; Mukesh Taneja; Virender S Sangwan
Journal:  Int Ophthalmol       Date:  2011-03-22       Impact factor: 2.031

4.  Boston type 1 keratoprosthesis for failed keratoplasty.

Authors:  Jonathan L Hager; David L Phillips; Kenneth M Goins; Anna S Kitzmann; Mark A Greiner; Alex W Cohen; Jeffrey D Welder; Michael D Wagoner
Journal:  Int Ophthalmol       Date:  2015-05-16       Impact factor: 2.031

5.  Risk factors for the development of retroprosthetic membranes with Boston keratoprosthesis type 1: multicenter study results.

Authors:  Christopher J Rudnisky; Michael W Belin; Amit Todani; Khalid Al-Arfaj; Jared D Ament; Brian J Zerbe; Joseph B Ciolino
Journal:  Ophthalmology       Date:  2012-02-22       Impact factor: 12.079

6.  Artificial corneas versus donor corneas for repeat corneal transplants.

Authors:  Masako Chen; Sueko M Ng; Esen K Akpek; Sumayya Ahmad
Journal:  Cochrane Database Syst Rev       Date:  2020-05-13

7.  Forty-five years of keratoprosthesis study and application at the Filatov Institute: a retrospective analysis of 1 060 cases.

Authors:  Stanislav Iakymenko
Journal:  Int J Ophthalmol       Date:  2013-06-18       Impact factor: 1.779

Review 8.  Artificial corneas versus donor corneas for repeat corneal transplants.

Authors:  Esen K Akpek; Majed Alkharashi; Frank S Hwang; Sueko M Ng; Kristina Lindsley
Journal:  Cochrane Database Syst Rev       Date:  2014-11-05

9.  Legeais BioKpro III keratoprosthesis implantation: long term results in seven patients.

Authors:  E J Hollick; S L Watson; J K G Dart; P J Luthert; B D S Allan
Journal:  Br J Ophthalmol       Date:  2006-09       Impact factor: 4.638

10.  Visual rehabilitation with keratoprosthesis after tenonplasty as the primary globe-saving procedure for severe ocular chemical injuries.

Authors:  Geetha Iyer; Bhaskar Srinivasan; Shweta Agarwal; Ravi Barbhaya
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-05-01       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.